Header Logo

Connection

GUILLERMO GARCIA-MANERO to Cell Line, Tumor

Back to Details
This is a "connection" page, showing publications GUILLERMO GARCIA-MANERO has written about Cell Line, Tumor.
GUILLERMO GARCIA-MANERO
Connection Strength
0.548
Cell Line, Tumor
  1. Analysis of class I and II histone deacetylase gene expression in human leukemia. Leuk Lymphoma. 2015; 56(12):3426-33.
    View in: PubMed
    Score: 0.045
  2. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-?B activation and enhances erythroid differentiation arrest. PLoS One. 2014; 9(4):e93404.
    View in: PubMed
    Score: 0.041
  3. DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia. Leukemia. 2014 Apr; 28(4):787-93.
    View in: PubMed
    Score: 0.040
  4. Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia. PLoS One. 2013; 8(4):e61807.
    View in: PubMed
    Score: 0.039
  5. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy. 2010 Oct; 6(7):976-8.
    View in: PubMed
    Score: 0.032
  6. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics. 2010 Aug 16; 5(6):499-508.
    View in: PubMed
    Score: 0.032
  7. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound ?-phenylethyl isothiocyanate. Blood. 2010 Oct 14; 116(15):2732-41.
    View in: PubMed
    Score: 0.032
  8. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res. 2010 Aug 01; 16(15):3923-32.
    View in: PubMed
    Score: 0.032
  9. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia. 2008 Aug; 22(8):1529-38.
    View in: PubMed
    Score: 0.027
  10. Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene. 2007 Mar 01; 26(10):1439-48.
    View in: PubMed
    Score: 0.024
  11. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res. 2005 Jul; 29(7):739-48.
    View in: PubMed
    Score: 0.022
  12. Identification of the Benzoimidazole Compound as a Selective FLT3 Inhibitor by Cell-Based High-Throughput Screening of a Diversity Library. J Med Chem. 2022 02 24; 65(4):3597-3605.
    View in: PubMed
    Score: 0.018
  13. Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification. Theranostics. 2019; 9(13):3768-3779.
    View in: PubMed
    Score: 0.015
  14. Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis. Cancer Commun (Lond). 2019 04 04; 39(1):17.
    View in: PubMed
    Score: 0.015
  15. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019 01 16; 10(1):244.
    View in: PubMed
    Score: 0.014
  16. Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. Leuk Res. 2017 08; 59:85-92.
    View in: PubMed
    Score: 0.013
  17. Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther. 2017 06; 16(6):1133-1144.
    View in: PubMed
    Score: 0.013
  18. c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. Clin Cancer Res. 2017 May 15; 23(10):2542-2555.
    View in: PubMed
    Score: 0.012
  19. Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation. Cancer Lett. 2016 07 28; 377(2):149-57.
    View in: PubMed
    Score: 0.012
  20. EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System. Mol Cancer Res. 2015 Jun; 13(6):982-92.
    View in: PubMed
    Score: 0.011
  21. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol. 2015 May; 169(3):344-51.
    View in: PubMed
    Score: 0.011
  22. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013 Sep; 23(9):1446-61.
    View in: PubMed
    Score: 0.010
  23. Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatr Blood Cancer. 2012 May; 58(5):682-9.
    View in: PubMed
    Score: 0.009
  24. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells. J Cell Mol Med. 2010 Jun; 14(6B):1777-92.
    View in: PubMed
    Score: 0.007
  25. Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leuk Res. 2009 Oct; 33(10):1361-6.
    View in: PubMed
    Score: 0.007
  26. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol. 2007 Jan; 20(1):54-62.
    View in: PubMed
    Score: 0.006
  27. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer. 2005 Mar 28; 92(6):1165-72.
    View in: PubMed
    Score: 0.006
  28. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res. 2004 Apr 01; 64(7):2411-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.